Junshi Biosciences Launches PD-1 Inhibitor Tuoyi for Advanced NSCLC in China
Junshi Biosciences (HKG: 1877, SHA: 688180), a China-based biopharmaceutical company, has held a national market...
Betta Pharmaceuticals Raises $140.5M for Drug Industrialization Base in Zhejiang
China’s Betta Pharmaceuticals Co., Ltd. (SHE: 300558) plans to raise RMB 1 billion ($140.5 million)...
China’s Volume-Based Procurement Cuts High-Value Medical Consumables Costs by 84%
The national high-value medical consumables alliance procurement office has released the results of the third...
Everest Medicines’ Xerava Approved in Hong Kong for Complicated Intra-Abdominal Infections
Everest Medicines Limited (HKG: 1952), a China-based biopharmaceutical company, has announced that it has received...
Ascletis Pharma Doses First Patient in Phase II Study of ASC41 for NASH
Ascletis Pharma Inc. (HKG: 1672), a China-based biopharmaceutical company, has announced that the first patient...
Transcenta’s TST004 Receives FDA IND Clearance for IgAN Treatment
China-based Transcenta Holding Ltd (HKG: 6628) has announced that it has received Investigational New Drug...
Connect Biopharma’s CBP-201 Shows Positive Results in Atopic Dermatitis Study
China-based Connect Biopharmaceuticals Ltd has announced the topline results of a pivotal clinical study for...
Kira Pharmaceuticals Gets FDA Green Light for Phase II Study of KP104 in SLE-TMA
Kira Pharmaceuticals, a Sino-US biotech company, has announced that it has received approval from the...
BGI Genomics Added to US Defense Department’s Investment Ban List
BGI Genomics Co., Ltd, a leading Chinese gene sequencing firm, has reportedly been added to...
Humanwell Healthcare’s Remimazolam Receives NMPA Approval for Bronchoscopy Use
China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has announced that it has received another...
Biosyngen’s First-in-Class Drug Candidate BRG01 Accepted for IND Review
Biosyngen has announced that its investigational new drug (IND) filing for the first-in-class (FIC) drug...
Zai Lab Reports Strong Revenue Growth in 2022 Interim Results
Chinese biopharmaceutical firm Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has released its 2022 interim...
Alphamab Oncology’s KN019 Achieves Primary Endpoint in Phase II RA Study
Suzhou-based biotech Alphamab Oncology (HKG: 9966) has announced that its China-based Phase II KN019-201 study,...
WuXi Biologics Partners with neoX Biotech to Advance AI-Driven Drug Development
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has entered into...
Luye Pharma’s Shandong Boan Partners with Shanghai Pharmaceutical for Biologics Manufacturing
China-based Luye Pharma Group (HKG: 2186) has announced that its controlling subsidiary, Shandong Boan Biotechnology...
Staidson’s STSP-0601 Receives Clinical Trial Approval for Hemophilia Treatment
Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204), a China-based pharmaceutical company, has announced that it...
Henlius Biotech Gets FDA Nod for HLX07 Clinical Study in CSCC
Shanghai Henlius Biotech (HKG: 2696) has announced that it has received approval from the US...
Suzhou Novoprotein Lists on Shanghai’s STAR Market for R&D Expansion
Suzhou Novoprotein Scientific Co., Ltd, a China-based provider of protein technology and application solutions, has...
Rainmed Medical’s caFFR System Receives TGA Approval for Coronary Disease Diagnosis
China-based Rainmed Medical Limited has announced that it has received market approval from Australia’s Therapeutic...
NeuShen Therapeutics Closes $20M Series Pre-A Financing for CNS Drug Development
NeuShen Therapeutics has announced the successful closure of a $20 million Series pre-A financing round...